Articles

Falsification and Pharmacovigilance: What Do Patients Get to See and What Should They Do with It?

Falsification and Pharmacovigilance: What Do Patients Get to See and What Should They Do with It?

The ‘Falsified medicines directive’ (2011/62/EU) and the ‘Pharmacovigilance regulation’ (No 1235/2010) will influence some of the information that patients receive about medicines. In both the directive and the regulation, several forms of visual communication are mentioned.

In this discussion piece Dr Karel van der Waarde explores the impact of the latest falsification and pharmacovigilance regulation on pharmaceutical packaging.

Why does packaging artwork matter?

Packaging artwork is an often forgotten back room process in most pharmaceutical companies, but the changing business environment has brought issues from this capability to the fore. Pharmaceutical and other healthcare companies are facing one of the most difficult periods in their history.

Top 3 Tips for Developing a Globally Applicable Labelling Strategy

Peter Schroeer, Director Europe, Quality Systems and Regulatory Affairs at Johnson & Johnson, joined Pharma IQ to talk about strategies for overcoming current compliance challenges the medical device market faces.